Evidence map›Paper›PMID 25048464›Full record

ArticlePloS one2014

BMP-non-responsive Sca1+ CD73+ CD44+ mouse bone marrow derived osteoprogenitor cells respond to combination of VEGF and BMP-6 to display enhanced osteoblastic differentiation and ectopic bone formation.

Vedavathi Madhu, Ching-Ju Li, Abhijit S Dighe, Gary Balian, Quanjun Cui

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Alveolar Bone Regeneration: Smart Biomaterials and Physical Stimulation.Journal of biomedical materials research. Part B, Applied biomaterials · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Vedavathi MadhuOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, United States of America.
Ching-Ju LiOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, United States of America.
Abhijit S DigheOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, United States of America.
Gary BalianOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, United States of America.
Quanjun CuiOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia, United States of America.

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
NCI NIH HHS P30 CA044579
6 · The paper itself

Abstract

Clinical trials on fracture repair have challenged the effectiveness of bone morphogenetic proteins (BMPs) but suggest that delivery of mesenchymal stem cells (MSCs) might be beneficial. It has also been reported that BMPs could not increase mineralization in several MSCs populations, which adds ambiguity to the use of BMPs. However, an exogenous supply of MSCs combined with vascular endothelial growth factor (VEGF) and BMPs is reported to synergistically enhance fracture repair in animal models. To elucidate the mechanism of this synergy, we investigated the osteoblastic differentiation of cloned mouse bone marrow derived MSCs (D1 cells) in vitro in response to human recombinant proteins of VEGF, BMPs (-2, -4, -6, -9) and the combination of VEGF with BMP-6 (most potent BMP). We further investigated ectopic bone formation induced by MSCs pre-conditioned with VEGF, BMP-6 or both. No significant increase in mineralization, phosphorylation of Smads 1/5/8 and expression of the ALP, COL1A1 and osterix genes was observed upon addition of VEGF or BMPs alone to the cells in culture. The lack of CD105, Alk1 and Alk6 expression in D1 cells correlated with poor response to BMPs indicating that a greater care in the selection of MSCs is necessary. Interestingly, the combination of VEGF and BMP-6 significantly increased the expression of ALP, COL1A1 and osterix genes and D1 cells pre-conditioned with VEGF and BMP-6 induced greater bone formation in vivo than the non-conditioned control cells or the cells pre-conditioned with either VEGF or BMP-6 alone. This enhanced bone formation by MSCs correlated with higher CADM1 expression and OPG/RANKL ratio in the implants. Thus, combined action of VEGF and BMP on MSCs enhances osteoblastic differentiation of MSCs and increases their bone forming ability, which cannot be achieved through use of BMPs alone. This strategy can be effectively used for bone repair.

Indexed as

AnimalsBone Marrow CellsBone Morphogenetic Protein 6Bone Morphogenetic ProteinsCell DifferentiationCells, CulturedMesenchymal Stem CellsMiceOsteogenesisVascular Endothelial Growth Factor ABone Morphogenetic Protein 6Bone Morphogenetic ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID25048464
PMCPMC4105618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.